Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Synthesis and biological evaluation of novel pyrimidine-5-carbonitriles featuring morpholine moiety as antitumor agents.

Helwa AA, Gedawy EM, Taher AT, Ed El-Ansary AK, Abou-Seri SM.

Future Med Chem. 2020 Feb 6. doi: 10.4155/fmc-2019-0146. [Epub ahead of print]

PMID:
32027179
2.

Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs.

Attia MH, Elrazaz EZ, El-Emam SZ, Taher AT, Abdel-Aziz HA, Abouzid KAM.

Bioorg Chem. 2020 Jan;94:103458. doi: 10.1016/j.bioorg.2019.103458. Epub 2019 Nov 21.

PMID:
31785854
3.

Iron deficiency anaemia revisited.

Cappellini MD, Musallam KM, Taher AT.

J Intern Med. 2020 Feb;287(2):153-170. doi: 10.1111/joim.13004. Epub 2019 Nov 12. Review.

PMID:
31665543
4.

Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.

Ahmed EM, Khalil NA, Taher AT, Refaey RH, Nissan YM.

Bioorg Chem. 2019 Nov;92:103272. doi: 10.1016/j.bioorg.2019.103272. Epub 2019 Sep 10.

PMID:
31539742
5.

Thalassemia and malignancy: An emerging concern?

Hodroj MH, Bou-Fakhredin R, Nour-Eldine W, Noureldine HA, Noureldine MHA, Taher AT.

Blood Rev. 2019 Sep;37:100585. doi: 10.1016/j.blre.2019.06.002. Epub 2019 Jun 22. Review.

PMID:
31253373
6.

Design, synthesis, modeling studies and biological screening of novel pyrazole derivatives as potential analgesic and anti-inflammatory agents.

Taher AT, Mostafa Sarg MT, El-Sayed Ali NR, Hilmy Elnagdi N.

Bioorg Chem. 2019 Aug;89:103023. doi: 10.1016/j.bioorg.2019.103023. Epub 2019 May 31.

PMID:
31185391
7.

Development of a thalassemia-related thrombosis risk scoring system.

Taher AT, Cappellini MD, Musallam KM.

Am J Hematol. 2019 Aug;94(8):E207-E209. doi: 10.1002/ajh.25502. Epub 2019 May 13. No abstract available.

PMID:
31056770
8.

Disparities in the risk of septic events in patients undergoing splenectomy for hematological malignancies (D-ROSE-PUSH): A study based on ACS-NSQIP database.

Saliba AN, Tamim H, Mailhac A, Jamali FR, Taher AT.

Am J Hematol. 2019 Aug;94(8):E205-E207. doi: 10.1002/ajh.25501. Epub 2019 May 7. No abstract available.

PMID:
31034629
9.

Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.

Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31. No abstract available.

10.

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.

Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB.

Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5.

11.

Deferasirox: Over a Decade of Experience in Thalassemia.

Moukalled NM, Bou-Fakhredin R, Taher AT.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018066. doi: 10.4084/MJHID.2018.066. eCollection 2018. Review.

12.

Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.

Taher AT, Weber S, Han J, Bruederle A, Porter JB.

Am J Hematol. 2019 Jan;94(1):E15-E17. doi: 10.1002/ajh.25322. Epub 2018 Nov 15. No abstract available.

13.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

14.

How I manage medical complications of β-thalassemia in adults.

Taher AT, Cappellini MD.

Blood. 2018 Oct 25;132(17):1781-1791. doi: 10.1182/blood-2018-06-818187. Epub 2018 Sep 11. Review.

15.

Assessment and study of knowledge and practice across different settings in Lebanon based on the recommendations of the American Society of Hematology Choosing Wisely campaign (ASK-PADS study).

Saliba AN, Moukhadder H, Beydoun H, Harb A, Farhat R, Ghaddara HA, Taher AT.

Am J Hematol. 2018 Nov;93(11):E350-E352. doi: 10.1002/ajh.25237. Epub 2018 Sep 26. No abstract available.

16.

Drug related bleeding as a cause of emergency department visits; a Lebanese tertiary care center experience.

Moukalled NM, Zakhia El-Doueihi PT, Salem RJ, Taher AT.

Eur J Intern Med. 2018 Sep;55:e10-e12. doi: 10.1016/j.ejim.2018.06.010. Epub 2018 Jun 14. No abstract available.

PMID:
29910101
17.

Iron overload in patients with myelodysplastic syndromes: An updated overview.

Moukalled NM, El Rassi FA, Temraz SN, Taher AT.

Cancer. 2018 Oct 15;124(20):3979-3989. doi: 10.1002/cncr.31550. Epub 2018 Jun 15. Review.

18.

The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.

Abdel-Razeq H, Finianos A, Taher AT.

Expert Rev Hematol. 2018 Jun;11(6):487-494. doi: 10.1080/17474086.2018.1480363. Epub 2018 Jun 1. Review.

PMID:
29791257
19.

Design, synthesis and biological evaluation of chromenopyrimidines as potential cytotoxic agents.

El-Bakhshawangy NM, El-Nassan HB, Kassab AE, Taher AT.

Future Med Chem. 2018 Jun 1;10(12):1465-1481. doi: 10.4155/fmc-2017-0324. Epub 2018 May 21.

PMID:
29779400
20.

Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens.

ElAwamy M, Mohammad H, Hussien A, Abutaleb NS, Hagras M, Serya RAT, Taher AT, Abouzid KA, Seleem MN, Mayhoub AS.

Eur J Med Chem. 2018 May 25;152:318-328. doi: 10.1016/j.ejmech.2018.04.049. Epub 2018 Apr 25.

PMID:
29734000
21.

Hepatocellular Carcinoma in a β-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic.

Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT.

Hemoglobin. 2018 Jan;42(1):58-60. doi: 10.1080/03630269.2018.1434197. Epub 2018 Mar 1.

PMID:
29493312
22.

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited.

Viprakasit V, Ajlan A, Aydinok Y, Al Ebadi BAA, Dewedar H, Ibrahim AS, Ragab L, Trad O, Wataify AS, Wong LLL, Taher AT.

Am J Hematol. 2018 Jun;93(6):E135-E137. doi: 10.1002/ajh.25075. Epub 2018 Mar 15. No abstract available.

23.

Thalassemia.

Taher AT.

Hematol Oncol Clin North Am. 2018 Apr;32(2):xv-xvi. doi: 10.1016/j.hoc.2017.12.003. Epub 2017 Dec 30. No abstract available.

PMID:
29458738
24.

Emerging Therapies.

Guerra A, Musallam KM, Taher AT, Rivella S.

Hematol Oncol Clin North Am. 2018 Apr;32(2):343-352. doi: 10.1016/j.hoc.2017.11.002. Epub 2017 Dec 15. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Jun;32(3):xiii.

25.

Hypercoagulability and Vascular Disease.

Taher AT, Cappellini MD, Bou-Fakhredin R, Coriu D, Musallam KM.

Hematol Oncol Clin North Am. 2018 Apr;32(2):237-245. doi: 10.1016/j.hoc.2017.11.001. Epub 2017 Dec 1. Review.

PMID:
29458729
26.

Clinical Complications and Their Management.

Marcon A, Motta I, Taher AT, Cappellini MD.

Hematol Oncol Clin North Am. 2018 Apr;32(2):223-236. doi: 10.1016/j.hoc.2017.11.005. Epub 2017 Dec 28. Review.

PMID:
29458728
27.

Ineffective Erythropoiesis: Anemia and Iron Overload.

Gupta R, Musallam KM, Taher AT, Rivella S.

Hematol Oncol Clin North Am. 2018 Apr;32(2):213-221. doi: 10.1016/j.hoc.2017.11.009. Epub 2017 Dec 29. Review.

28.

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?

Cappellini MD, Porter JB, Viprakasit V, Taher AT.

Blood Rev. 2018 Jul;32(4):300-311. doi: 10.1016/j.blre.2018.02.001. Epub 2018 Feb 12. Review.

29.

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.

Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT.

Int J Mol Sci. 2018 Jan 8;19(1). pii: E182. doi: 10.3390/ijms19010182. Review.

30.

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

Bou-Fakhredin R, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT.

Int J Mol Sci. 2017 Dec 20;18(12). pii: E2778. doi: 10.3390/ijms18122778. Review.

31.

Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.

Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT.

Hemoglobin. 2017 Jul - Nov;41(4-6):267-273. doi: 10.1080/03630269.2017.1408646. Epub 2017 Dec 18.

PMID:
29251012
32.

Iron overload in thalassemia: different organs at different rates.

Taher AT, Saliba AN.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271. doi: 10.1182/asheducation-2017.1.265. Review.

33.

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Taher AT, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A, Rivella S, Hollaender N, Mahuzier B, Gadbaw B, Aydinok Y.

Blood. 2018 Jan 11;131(2):263-265. doi: 10.1182/blood-2017-06-790121. Epub 2017 Nov 2. No abstract available.

34.

Iron deficiency beyond erythropoiesis: should we be concerned?

Musallam KM, Taher AT.

Curr Med Res Opin. 2018 Jan;34(1):81-93. doi: 10.1080/03007995.2017.1394833. Epub 2017 Nov 3. Review.

PMID:
29050512
35.

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Jeglinski BI, Pietropaolo K, Berk G, Viprakasit V.

Am J Hematol. 2017 Dec;92(12):1356-1361. doi: 10.1002/ajh.24914. Epub 2017 Oct 31.

36.

Causes of hospital admission in β-thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center.

Saliba AN, Moukhadder HM, Harb A, Beydoun H, Bou-Fakhredin R, Taher AT.

Am J Hematol. 2017 Dec;92(12):E652-E653. doi: 10.1002/ajh.24900. Epub 2017 Sep 28. No abstract available.

37.

Thalassaemia.

Taher AT, Weatherall DJ, Cappellini MD.

Lancet. 2018 Jan 13;391(10116):155-167. doi: 10.1016/S0140-6736(17)31822-6. Epub 2017 Jul 31. Review.

PMID:
28774421
38.

Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management.

Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM; IRON CORE Group.

Am J Hematol. 2017 Oct;92(10):1068-1078. doi: 10.1002/ajh.24820. Epub 2017 Jul 7. Review.

39.

Revisiting beta thalassemia intermedia: past, present, and future prospects.

Ben Salah N, Bou-Fakhredin R, Mellouli F, Taher AT.

Hematology. 2017 Dec;22(10):607-616. doi: 10.1080/10245332.2017.1333246. Epub 2017 Jun 7.

PMID:
28589785
40.

Rheumatological complications of beta-thalassaemia: an overview.

Noureldine MHA, Taher AT, Haydar AA, Berjawi A, Khamashta MA, Uthman I.

Rheumatology (Oxford). 2018 Jan 1;57(1):19-27. doi: 10.1093/rheumatology/kex058. Review.

PMID:
28371817
41.

Pregnancy in β-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes.

Roumi JE, Moukhadder HM, Graziadei G, Pennisi M, Cappellini MD, Taher AT.

Am J Hematol. 2017 Jun;92(6):E96-E99. doi: 10.1002/ajh.24690. Epub 2017 Mar 4. No abstract available.

42.

New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.

Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB.

Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.

43.

Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor.

Moukhadder HM, Halawi R, Cappellini MD, Taher AT.

Cancer. 2017 May 15;123(6):1073. doi: 10.1002/cncr.30550. Epub 2017 Jan 13. No abstract available.

44.

Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable.

Saliba AN, Musallam KM, Cappellini MD, Graziadei G, Daar S, Viprakasit V, Taher AT.

Am J Hematol. 2017 Mar;92(3):E35-E37. doi: 10.1002/ajh.24628. Epub 2017 Feb 1. No abstract available.

45.

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.

Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD.

Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016. No abstract available.

46.

Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT.

Br J Haematol. 2017 Jan;176(2):288-299. doi: 10.1111/bjh.14373. Epub 2016 Dec 5.

47.

Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.

Moukhadder HM, Halawi R, Cappellini MD, Taher AT.

Cancer. 2017 Mar 1;123(5):751-758. doi: 10.1002/cncr.30462. Epub 2016 Dec 1. Review.

48.

Synthesis and cytotoxic activity of certain benzothiazole derivatives against human MCF-7 cancer cell line.

Mohamed LW, Taher AT, Rady GS, Ali MM, Mahmoud AE.

Chem Biol Drug Des. 2017 Apr;89(4):566-576. doi: 10.1111/cbdd.12879. Epub 2016 Nov 2.

PMID:
27700014
49.

Synthesis and cytotoxic activity of certain trisubstituted azetidin-2-one derivatives as a cis-restricted combretastatin A-4 analogues.

Elmeligie S, Taher AT, Khalil NA, El-Said AH.

Arch Pharm Res. 2017 Jan;40(1):13-24. doi: 10.1007/s12272-016-0849-y. Epub 2016 Oct 17.

PMID:
27747473
50.

Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds.

El-Meligie S, Taher AT, Kamal AM, Youssef A.

Eur J Med Chem. 2017 Jan 27;126:52-60. doi: 10.1016/j.ejmech.2016.09.099. Epub 2016 Oct 1.

PMID:
27744186

Supplemental Content

Loading ...
Support Center